Psychotropic Medication Use by Children with Autism Served in Publicly Funded Mental Health Settings

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Barbara Caplan ◽  
Colby Chlebowski ◽  
Gina May ◽  
Mary J. Baker-Ericzén ◽  
Willard Connor ◽  
...  
Author(s):  
Elizabeth Wall-Wieler ◽  
Leslie Roos ◽  
James Bolton

IntroductionMothers have increased mental illness such as anxiety and depression after the death of a child. Objectives and ApproachThe mental health of all mothers who experience the death of an infant (< 1 years old) in Manitoba, Canada between April 1, 1999, and March 31, 2011 (n = 534) is examined in the four years leading up to, and the four years following, the death of their child to determine how long increased levels of mental-health realted outcomes remain elevated after the death of an infant. Mental health-related outcomes of these mothers are compared with a matched (3:1) cohort of mothers who did not experience the death of a child (n = 1,602). ResultsCompared with mothers who did not experience the death of a child, mothers experiencing this event had higher rates of anxiety diagnoses and psychotropic prescriptions starting 6 months before the death. Elevated rates of anxiety continued for the first year and elevated rates of psychotropic prescriptions continued for six months after the death of the child. Mothers who experienced the death of a child had higher rates of depression diagnoses in the year after the death. Relative rates (RR) of depression (RR = 4.94), anxiety (RR = 2.21), and psychotropic medication use (RR = 3.18) were highest in the six months after the child’s death. Conclusion/ImplicationsElevated rates of depression, anxiety, and psychotropic medication use after the death of a child end within one year of the child’s death.


PEDIATRICS ◽  
2020 ◽  
Vol 145 (Supplement 1) ◽  
pp. S99-S107 ◽  
Author(s):  
Daniela Ziskind ◽  
Amanda Bennett ◽  
Abbas Jawad ◽  
Nathan Blum

2012 ◽  
Vol 51 (10) ◽  
pp. 923-927 ◽  
Author(s):  
P. Gail Williams ◽  
Charles Woods ◽  
Michelle Stevenson ◽  
Deborah Winders Davis ◽  
Paula Radmacher ◽  
...  

2018 ◽  
Vol Volume 10 ◽  
pp. 1073-1082 ◽  
Author(s):  
Yael Nillni ◽  
Amelia Wesselink ◽  
Elizabeth Hatch ◽  
Ellen Mikkelsen ◽  
Jaimie L Gradus ◽  
...  

2020 ◽  
Vol 29 ◽  
Author(s):  
Henry J. Whittle ◽  
William R. Wolfe ◽  
Lila A. Sheira ◽  
Edward A. Frongillo ◽  
Kartika Palar ◽  
...  

Abstract Aims Psychotropic prescription rates continue to increase in the United States (USA). Few studies have investigated whether social-structural factors may play a role in psychotropic medication use independent of mental illness. Food insecurity is prevalent among people living with HIV in the USA and has been associated with poor mental health. We investigated whether food insecurity was associated with psychotropic medication use independent of the symptoms of depression and anxiety among women living with HIV in the USA. Methods We used cross-sectional data from the Women's Interagency HIV Study (WIHS), a nationwide cohort study. Food security (FS) was the primary explanatory variable, measured using the Household Food Security Survey Module. First, we used multivariable linear regressions to test whether FS was associated with symptoms of depression (Center for Epidemiologic Studies Depression [CESD] score), generalised anxiety disorder (GAD-7 score) and mental health-related quality of life (MOS-HIV Mental Health Summary score; MHS). Next, we examined associations of FS with the use of any psychotropic medications, including antidepressants, sedatives and antipsychotics, using multivariable logistic regressions adjusting for age, race/ethnicity, income, education and alcohol and substance use. In separate models, we additionally adjusted for symptoms of depression (CESD score) and anxiety (GAD-7 score). Results Of the 905 women in the sample, two-thirds were African-American. Lower FS (i.e. worse food insecurity) was associated with greater symptoms of depression and anxiety in a dose–response relationship. For the psychotropic medication outcomes, marginal and low FS were associated with 2.06 (p < 0.001; 95% confidence interval [CI] = 1.36–3.13) and 1.99 (p < 0.01; 95% CI = 1.26–3.15) times higher odds of any psychotropic medication use, respectively, before adjusting for depression and anxiety. The association of very low FS with any psychotropic medication use was not statistically significant. A similar pattern was found for antidepressant and sedative use. After additionally adjusting for CESD and GAD-7 scores, marginal FS remained associated with 1.93 (p < 0.05; 95% CI = 1.16–3.19) times higher odds of any psychotropic medication use. Very low FS, conversely, was significantly associated with lower odds of antidepressant use (adjusted odds ratio = 0.42; p < 0.05; 95% CI = 0.19–0.96). Conclusions Marginal FS was associated with higher odds of using psychotropic medications independent of depression and anxiety, while very low FS was associated with lower odds. These complex findings may indicate that people experiencing very low FS face barriers to accessing mental health services, while those experiencing marginal FS who do access services are more likely to be prescribed psychotropic medications for distress arising from social and structural factors.


2005 ◽  
Vol 29 (12) ◽  
pp. 1359-1372 ◽  
Author(s):  
David S. Mandell ◽  
Christine M. Walrath ◽  
Brigitte Manteuffel ◽  
Gina Sgro ◽  
Jennifer A. Pinto-Martin

Autism ◽  
2017 ◽  
Vol 22 (8) ◽  
pp. 938-952 ◽  
Author(s):  
Lauren Brookman-Frazee ◽  
Nicole Stadnick ◽  
Colby Chlebowski ◽  
Mary Baker-Ericzén ◽  
William Ganger

Publicly funded mental health programs play a significant role in serving children with autism spectrum disorder. Understanding patterns of psychiatric comorbidity for this population within mental health settings is important to implement appropriately tailored interventions. This study (1) describes patterns of psychiatric comorbidity in children with autism spectrum disorder who present to mental health services with challenging behaviors and (2) identifies child characteristics associated with comorbid conditions. Data are drawn from baseline assessments from 201 children with autism spectrum disorder who participated in a community effectiveness trial across 29 publicly funded mental health programs. Non-autism spectrum disorder diagnoses were assessed using an adapted Mini-International Neuropsychiatric Interview, parent version. Approximately 92% of children met criteria for at least one non-autism spectrum disorder diagnosis (78% attention deficit hyperactivity disorder, 58% oppositional defiant disorder, 56% anxiety, 30% mood). Logistic regression indicated that child gender and clinical characteristics were differentially associated with meeting criteria for attention deficit hyperactivity disorder, oppositional defiant disorder, an anxiety, or a mood disorder. Exploratory analyses supported a link between challenging behaviors and mood disorder symptoms and revealed high prevalence of these symptoms in this autism spectrum disorder population. Findings provide direction for tailoring intervention to address a broad range of clinical issues for youth with autism spectrum disorder served in mental health settings.


Sign in / Sign up

Export Citation Format

Share Document